![]() |
| Home | | Obesity | | Diabetes | | Prostate | | Andropause | | Testicles | | Sexual Health | | Vasectomy | | Hair Loss | | Other Conditions | | Public Releases | | Blog | | Forum |
19
Apr
19
Apr
Prostate specific antigen (PSA) screening is widely used for the early detection of prostate cancer, but remains highly controversial, as it became widespread long before evidence to prove its value.
There is now evidence that PSA screening can reduce prostate cancer mortality in men who would not otherwise be screened. However, this can come at considerable harm.
As there is little evidence to support many aspects of screening guidelines, researchers from Sweden and the USA carried out a case-control study taking data from the Malmo Preventative Project (MPP) cohort, in an attempt to develop an evidence-based scheme for prostate cancer testing.
The researchers conclude that PSA levels are informative of the current risk of cancer as well as being “predictive of the future risk of prostate cancer” and any cancer-specific death.
They say that screening programmes can be designed so as to “reduce the risk of over-diagnosis whilst still enabling early cancer detection for men at highest risk of death from prostate cancer”.
16
Apr
16
Apr
16
Apr
16
Apr
16
Apr
12
Apr
Travelling from Perth to Melbourne, the ‘Male Bag Run’ passed through South Australia this week, its swarm of red bikes making it across the Nullarbor, through the outback to Adelaide, and down to Mount Gambier.
11
Apr
11
Apr
A new study finds that prostate cancer spreads more quickly and is more likely to be fatal in men who have inherited a faulty BRCA2 gene. The researchers say such patients should be treated straight away with surgery or radiotherapy rather than just be monitored.
Research has already established that men who inherit a faulty BRCA2 gene have a higher risk of developing prostate cancer, but this, the largest study of its kind, is the first to show that the faulty gene also means carriers are more likely to experience more rapid spread of the disease and poorer survival.
The study, reported this week in the Journal of Clinical Oncology, poses a potential challenge to health systems like the UK’s NHS where carriers of the faulty gene are offered the same prostate cancer treatment options as non-carriers.
This section need flickr plugin to be activated..
